Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivanisiran in Ocular Pain/Dry Eye
NCT01776658Phase 2Completed
- Sponsor
- Sylentis
- Start
- Nov 2012
- Primary completion
- Apr 2015
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of tivanisiran in dry eye syndrome (DED), sponsored by Sylentis. Started Nov 2012; status: completed.
02
Drugs
tivanisiran
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT01776658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01776658.